Nektar TherapeuticsNKTRNASDAQ

Revenue (LTM)

$55M

-43.9% YoY

Net Income (LTM)

$-164M

-37.9% YoY

Free Cash Flow

$-209M

Revenue CAGR (5Y)

-14.2%

—Marginsstable

FCF($0.2B)

Unprofitable

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Revenue	102	92↓9.7%	90↓2.1%	98↑9.2%	55↓43.9%
Gross Profit	77	70↓8.6%	53↓24.1%	68↑26.7%	55↓18.5%
Operating Income	-446	-240↑46.1%	-137↑42.8%	-105↑23.5%	-131↓24.3%
Net Income	-524	-368↑29.7%	-276↑25.0%	-119↑56.9%	-164↓37.9%
EBITDA	-462	-324↑29.9%	-243↑24.9%	-87↑64.3%	-130↓49.7%
EPS Diluted	-42.90	-29.51↑31.2%	-21.79↑26.2%	-8.68↑60.2%	-9.73↓12.1%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Cash & Equivalents	25	88↑249.9%	35↓60.0%	44↑25.4%	15↓65.8%
Total Current Assets	796	546↓31.4%	331↓39.4%	261↓21.0%	266↑1.9%
Total Assets	1,117	711↓36.4%	398↓44.0%	304↓23.7%	280↓7.7%
Total Current Liabilities	85	68↓19.9%	51↓24.8%	61↑19.8%	54↓12.8%
Total Liabilities	438	344↓21.4%	267↓22.4%	243↓9.0%	191↓21.6%
Total Equity	680	367↓46.0%	131↓64.3%	61↓53.6%	90↑47.9%
Total Debt	143	131↓8.2%	118↓10.4%	103↓12.9%	149↑45.2%
Net Debt	118	43↓63.3%	82↑90.7%	58↓29.3%	134↑129.4%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Operating Cash Flow	-413	-304↑26.3%	-193↑36.6%	-176↑8.8%	-209↓18.7%
Capital Expenditure	-15	-6↑62.1%	-1↑84.8%	-1↓69.7%	-0↑88.4%
Free Cash Flow	-428	-310↑27.6%	-193↑37.5%	-177↑8.4%	-209↓17.8%
Stock-Based Comp	95	57↓39.5%	33↓41.8%	22↓35.3%	13↓41.5%
Net Change in Cash	-174	63↑136.3%	-53↓184.0%	9↑116.9%	-29↓424.6%

Values in millions except EPS · Ratios shown as percentages · Click any metric to drill down

Explore More

Filter and sort all 500 stocks

Today's biggest gainers and losers

Visual sector performance